Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Mallinckrodt Stock Is Sinking Today

By Keith Speights - Jul 17, 2019 at 11:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another bump in the road for Acthar is weighing on the drugmaker.

What happened

Shares of Mallinckrodt ( MNK ) are sinking today, down 8.3% as of 11:30 a.m. EDT after falling as much as 12.2% earlier in the session. The drugmaker announced on Tuesday after the market closed that it was discontinuing the phase 2b clinical study evaluating Acthar Gel in treating amyotrophic lateral sclerosis (ALS).

Mallinckrodt stated that the study was being permanently halted on the recommendation of the study's independent data and safety monitoring board. The board expressed a concern that more ALS patients taking Acthar were developing pneumonia compared to patients on placebo. 

Doctor holding up hand as if to stop something

Image source: Getty Images.

So what

The discontinuation of the study means that Mallinckrodt won't be able to pick up yet another approved indication for Acthar in treating ALS. Acthar is currently approved by the U.S. Food and Drug Administration (FDA) for 19 indications.

However, other clinical studies that are in progress for Acthar aren't impacted by the ALS setback. In Mallinckrodt's first-quarter conference call, company executives didn't talk about the ALS study at all. Instead, they focused on upcoming results for clinical studies evaluating Acthar in treating multiple sclerosis and rheumatoid arthritis. Mallinckrodt announced positive results from its phase 4 rheumatoid arthritis clinical study in June.

The reality is that the deck was stacked against Acthar in treating ALS from the beginning. Mallinckrodt Chief Scientific Officer Steven Romano admitted this, stating, "Though the probability of success for the ALS population was acknowledged as being low, this study was initiated based on compelling analyses carried out following the completion of a small pilot study, and we were hopeful it would have translated into a benefit for this group of patients in great need of effective therapies."

Now what

Mallinckrodt's biggest challenge now has nothing to do with the ALS study discontinuation. In May, the company filed a lawsuit against the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS). The goal of this lawsuit is to set aside a CMS decision that Mallinckrodt is afraid would eliminate its net sales of Acthar Gel to Medicaid.

There appear to be too many dark clouds hanging over Mallinckrodt right now to make this stock a great pick to buy. Investors are probably better off staying on the sidelines.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Public Limited Company Stock Quote
Mallinckrodt Public Limited Company

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.